New in Oncology - Aug 13, 2026
Catching resistance early, pushing remission deeper: ctDNA-guided switches, durable CAR-T, and perioperative EV–pembro—plus 9 trials
Oncology Intel by Sagely Health
Your go-to weekly source of clinical trials news and treatment insights.
Subscribe:.rss.atom.json.md.m3u.pls
Live Last read · last published · next check
Latest episodes
New in Oncology - Aug 6, 2026
Oncology didn’t take a summer vacation: 16 standouts among 66 notable findings—plus 10 trials
New in Oncology - July 16, 2026
Precision medicine keeps winning: adjuvant RET therapy, first-line BRAF CRC, personalized melanoma vaccines, menin AML, and brain metastasis radiation breakthroughs—plus 15 new trials.
DOUBLE ISSUE: New in Oncology - July 8, 2026
ASCO’s long tail keeps delivering in this massive issue: RCC immunotherapy, myeloma CAR-T, AML triplets, PDAC combinations, bladder ADCs, CRC bispecifics, and KRAS T-cell targeting—plus 14 new trials.
New in Oncology - June 25, 2026
ASCO aftershocks keep rolling: melanoma vaccines, MSI-H colon de-escalation, HER2 gastric survival, bladder ADCs, prostate intensification, and head-and-neck IO boosts—plus 32 new trials.
New in Oncology - June 18, 2026
Breast cancer takes center stage this week: HER2 durability, smarter endocrine resistance, and ADCs reshaping TNBC—plus 29 new trials.
New in Oncology - June 11, 2026
The ASCO NSCLC flood is here: 42 notable lung-cancer findings, 7 worth spotlighting first—plus 20 new trials.
New in Oncology - June 4, 2026
KRAS lung cancer strategies break through, EV+pembro shows a bladder survival tail, and ADC+IO raises the bar in frontline TNBC—plus 25 new trials.
New in Oncology - May 28, 2026
Dose-painting GBM, knife-free kidney ablation, a microbiome lift in lung cancer, and HER2 ADC activity across gynecologic tumors—plus 33 new trials
New in Oncology - May 21, 2026
Targeting gets more precise: rare HER2-low salivary responses, surgery-sparing facial SCC, broad RAS control in PDAC, and CLDN18.2 gastric gains—plus 15 new trials.